Clinical trials: Cell Transplantation
IFD Post-HSCT
Posaconazole vs Itraconazole in Preventing IFD Post-HSCT
Invasive Fungal Disease (IFD) after haematopoietic stem cell transplantation (HSCT) remain a clinical challenge.The studay aims to compare the efficacy and safety of posaconazole oral suspension vs itraconazole oral solution in…
- Trial name
- NCT03631602
- Testing
- antifungal prophylaxis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Medical University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation
This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
- Trial name
- NCT02312102
- Testing
- Lenalidomide, Velcade
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Nodal T-follicular Helper Cell Lymphoma
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
This study is conducted to evaluate the efficacy and safety of linperlisib combined with CHOP regimen followed by autologous hematopoietic stem cell transplantation and linperlisib monotherapy maintenance for newly diagnosed…
- Trial name
- NCT06347653
- Testing
- linperlisib combined with CHOP regimen
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking University
Hematologic Malignancies
Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation
Transfusion of red blood cells (RBCs) is important for the care of patients undergoing stem cell transplantation. Stem cell transplants are used to treat blood cancers and bone marrow disorders.
- Trial name
- TRIST (NCT01237639)
- Testing
- Red blood cell Transfusion
- Where
- 4 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Ottawa Hospital Research Institute
Myelofibrosis
JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis
JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II
- Trial name
- NCT01795677
- Testing
- Ruxolotinib
- Where
- France
- Volunteers
- 78 people
- Sponsor
- French Innovative Leukemia Organisation
Multiple Myeloma and Plasma Cell Neoplasm
Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00003195
- Testing
- recombinant interferon alfa, busulfan, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma
Trial Title: FiTNEss (UK-MRA Myeloma XIV) - Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma Overview: A phase III, multi-centre, randomised controlled trial to compare standard…
- Trial name
- FiTNEss (NCT03720041)
- Testing
- R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide + ixazomib maintenance
- Where
- 110 sites in United Kingdom
- Volunteers
- 740 people
- Sponsor
- University of Leeds
Leukemia
Interferon-α After DLI for the Prevention of Relapse
This study aimed to evaluate the efficacy of interferon α after prophylactic donor lymphocyte infusion (DLI) among high-risk acute leukemia patients undergone unmanipulated blood and marrow transplantation.
- Trial name
- IDPR-HSCT (NCT02568241)
- Testing
- Interferon Alfa-2b
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Peking University People's Hospital
Multiple Myeloma, Lymphoma
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
The goal of this study is to determine the safety and clinical effect of combined checkpoint inhibition administered after autologous hematopoietic stem cell transplantation in each of six clinical cohorts of high risk and…
- Trial name
- CPIT001 (NCT02681302)
- Testing
- Ipilimumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Hackensack Meridian Health
Stem Cell Transplantation, Hematopoietic
Evaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation
The primary objective of this study is to demonstrate the efficacy of a pre-transplant, interval exercise training (IET) intervention, in increasing peak oxygen uptake (VO2peak) scores on cycle ergometry.
- Trial name
- NCT02577939
- Testing
- Interval Exercise Training (IET)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who…
- Trial name
- NCT02775903
- Testing
- Azacitidine, Durvalumab
- Where
- 103 sites in United States, Austria and 10 more
- Volunteers
- 213 people
- Sponsor
- Celgene
Neuroblastoma
Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors
Allogeneic stem cell transplantation has been explored for patients with high risk neuroblastoma. Results have been mixed, with only small series and case reports.
- Trial name
- STALLO (NCT01462396)
- Testing
- CD34+ cells selected with the Miltenyi Clinimacs machine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Mercy Hospital Kansas City
Multiple Myeloma, Recurrent Multiple Myeloma
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
This phase I trial investigates the side effects and best dose of ²¹¹At-OKT10-B10 when given together with fludarabine, alone or in combination with cyclophosphamide and low-dose total-body irradiation (TBI) before donor stem…
- Conditions
- Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT04579523
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Ovarian Cancer
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- ETC (NCT00005612)
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma in Relapse
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate…
- Trial name
- NCT03030261
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 3 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV infections better than taking…
- Trial name
- NCT06639854
- Testing
- Hematopoietic Cell Transplant, Letermovir
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia
RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Trial name
- NCT00553202
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 52 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Kidney Transplant, Kidney Failure
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
This research study is for people who have been waiting for a kidney transplant for at least one year, and who have a cPRA of 99.5% or higher.
- Conditions
- Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
- Trial name
- NCT06056102
- Testing
- Cyclophosphamide, CART-BCMA, huCART19
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Stem Cell Transplant Complications
Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis
Currently, the application status of MSCs as treatment modalities in IPF is still in its infancy and remains exploratory. Although a number of safety and efficacy clinical trials of MSCs as therapeutic options in immune-mediated…
- Trial name
- NCT03187431
- Testing
- autologous bone marrow mesenchymal stem cells
- Volunteers
- 12 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.